Ardelyx and Knight Collaborate to Bring Tenapanor to Patients in Canada

License Agreement Advances First-in-Class Tenapanor for IBS-C and Hyperphosphatemia in Canada Ardelyx to Receive Up to CAD 25 Million in Upfront Payment and Subsequent Milestones FREMONT, Calif., March 19, 2018 -- (Healthcare Sales & Marketing Networ... Biopharmaceuticals, Gastroenterology, Licensing Ardelyx, Knight Therapeutics, tenapanor, inflammatory bowel
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news